| 0 (0%) | 09-27 09:29 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 41.4 | 1-year : | 48.36 |
| Resists | First : | 35.45 | Second : | 41.4 |
| Pivot price | 31.99 |
|||
| Supports | First : | 30.02 | Second : | 26.66 |
| MAs | MA(5) : | 32.19  |
MA(20) : | 31.92 |
| MA(100) : | 34.25 |
MA(250) : | 31.37 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 77.2 |
D(3) : | 79.2 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 44.34 | Low : | 23.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ZLAB ] has closed above bottom band by 41.5%. Bollinger Bands are 39.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.04 - 32.24 | 32.24 - 32.38 |
| Low: | 30.68 - 30.93 | 30.93 - 31.11 |
| Close: | 31.29 - 31.66 | 31.66 - 31.92 |
Wed, 17 Sep 2025
Zai Lab (NasdaqGM:ZLAB) Valuation in Focus After FORTITUDE-101 Data Tempers Bemarituzumab Hopes - simplywall.st
Tue, 16 Sep 2025
Zai Lab Limited (ZLAB): A Bull Case Theory - MSN
Tue, 16 Sep 2025
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy? - MarketBeat
Thu, 11 Sep 2025
$ZLAB stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
Wed, 10 Sep 2025
Why Zai Lab (ZLAB) Is Down 5.5% After Diminished Final Results for Bemarituzumab in Gastric Cancer - Sahm
Wed, 10 Sep 2025
Why Zai Lab (ZLAB) Is Down 5.5% After Diminished Final Results for Bemarituzumab in Gastric Cancer - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 111 (M) |
| Shares Float | 1,080 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 42.6 (%) |
| Shares Short | 4,740 (K) |
| Shares Short P.Month | 4,570 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.19 |
| Profit Margin | -49.7 % |
| Operating Margin | -50 % |
| Return on Assets (ttm) | -14.4 % |
| Return on Equity (ttm) | -28.5 % |
| Qtrly Rev. Growth | 9.3 % |
| Gross Profit (p.s.) | 0.33 |
| Sales Per Share | 3.84 |
| EBITDA (p.s.) | -2.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -175 (M) |
| Levered Free Cash Flow | -217 (M) |
| PE Ratio | -15.82 |
| PEG Ratio | 0 |
| Price to Book value | 4.39 |
| Price to Sales | 8.22 |
| Price to Cash Flow | -20.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|